Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026. After this sale, she directly holds 824,039 common shares. The filing also lists outstanding employee stock options, including 16,470 options exercisable at $8.82 expiring in 2027 and 64,950 options at $67.85 expiring in 2030. The transactions were made under a pre-established Rule 10b5-1 trading plan.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock. On June 24, 2026, Cho sold 14,205 shares at $89.75 per share. After this transaction, he continues to hold 105,141 shares directly.
The filing notes that this sale was carried out under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026, indicating the trade was pre-planned rather than timed at discretion, which often signals routine portfolio management rather than a change in outlook.
Emily M. Leproust reported a series of sales of common stock between 04/21/2026 and 06/22/2026.
Transactions listed include 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46, along with multiple other dated sales and dollar amounts shown in the filing.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported a small mandated share sale tied to equity compensation. On June 22, 2026, she sold 291 shares of common stock at $87.3224 per share solely to cover tax withholding on vesting Restricted Stock Units. After this tax-related transaction, she directly held 120,414 shares of Twist Bioscience common stock.
Twist Bioscience Corp executive Dennis Cho reported a mandated sale of 346 shares of Common Stock. The shares were sold at an average price of $87.3224 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
According to the filing footnote, this was a required "sell to cover" transaction and not a discretionary trade by Cho. Following this tax-related sale, he directly owned 119,346 shares of Twist Bioscience Common Stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 1,688 shares of common stock at $87.3224 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
After this transaction, Leproust directly holds 842,919 shares of Twist Bioscience common stock. She also retains employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share that are outstanding and expire on August 31, 2030.
Twist Bioscience-related reporting person reported sales of Common Stock in multiple transactions. The largest single sale listed was 14,205 shares for $990,798.75 on 05/29/2026, with additional sales of 1,962 shares ($112,125.95), 1,642 shares ($87,447.34), 402 shares ($28,077.37), and 346 shares ($30,213.55) on the dates shown.
Emily M. Leproust reported multiple sales of Common stock. The filings list open‑market dispositions on several dates between 04/21/2026 and 06/08/2026 with individual trades such as 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46. The excerpt also records a restricted stock vesting of 1,688 shares on 06/18/2026.
Issuer reported insider sales and a restricted-stock vesting. The filing lists a Restricted Stock Vesting of 346 shares on 06/18/2026 recorded as compensation. It also discloses multiple sales by Dennis H. Cho: 1,962 shares on 05/04/2026, 1,642 shares on 05/21/2026, 14,205 shares on 05/29/2026, and 402 shares on 06/08/2026, with proceeds shown in the filing for each sale.
Form 144 notice: proposed sale of Common Stock related to TWST. The filing lists a proposed sale of 291 shares tied to restricted stock vesting on 06/18/2026 described as Compensation. The filing also reports multiple sales by Paula Green during the past three months: 1,116 shares on 05/04/2026, 1,399 shares on 05/21/2026, 884 shares on 06/08/2026, and 26,137 shares on 06/15/2026, each with the dollar amounts shown in the excerpt.